Callan JMB Inc(CJMB) - 2025 Q1 - Quarterly Results

First Quarter 2025 Results and Business Update Management Commentary The CEO highlighted the company's strategy to scale its business model into high-growth sectors by leveraging its core strengths in advanced logistics - The company is strategically expanding into new, high-growth markets including GLP-1 pharmaceutical transportation, specialized compounding pharmacy logistics, and premium food packaging services[2] - A national expansion of emergency preparedness and response operations is underway, with a focus on untapped metropolitan areas and states[2] - The appointment of Christopher Shields as Senior Vice President of Emergency Preparedness & Response/Government Affairs is intended to accelerate geographic expansion[2] Business Highlights In early 2025, Callan JMB successfully completed its IPO, raising approximately $5.7 million, strengthened its emergency response division, and secured significant state-level contracts - Completed its Initial Public Offering (IPO) on February 6, 2025, raising gross proceeds of approximately $5.7 million[1][3] - Secured a new five-year contract with the Oregon Health Authority and renewed its arrangement with the Texas Department of State Health Services (DSHS) for emergency preparedness[3] - Appointed former Chicago Department of Public Health Assistant Commissioner, Christopher Shields, as SVP, Emergency Preparedness & Response/Government Affairs[3] - Launched a comprehensive lease program for vaccine management to reduce the financial burden on government and private organizations[3] Financial Results Financial Highlights for the First Quarter Ended March 31, 2025 For the first quarter of 2025, Callan JMB reported revenue of $1.45 million, a decrease attributed to lower demand for emergency preparedness services, and posted a net loss of $1.2 million due to increased SG&A expenses Q1 2025 Financial Summary | Metric | Value | Note | | :--- | :--- | :--- | | Revenue | $1.45 million | Decrease due to lower demand for emergency preparedness services | | Gross Profit | $0.6 million | - | | Gross Margin | 42.5% | - | | SG&A Expenses | $1.9 million | Increased due to IPO costs and senior staff hires | | Operating Loss | ($1.2) million | - | | Net Loss | ($1.2) million | - | Condensed Consolidated Financial Statements The consolidated financial statements detail the company's financial position and performance, reflecting a strengthened cash position post-IPO, a year-over-year revenue decline, and increased net loss due to higher operating expenses Condensed Consolidated Balance Sheets As of March 31, 2025, the company's balance sheet strengthened significantly compared to December 31, 2024, with cash increasing to $5.2 million from $2.1 million, driven by IPO proceeds Balance Sheet Comparison | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash | $5,219,929 | $2,097,945 | | Total Current Assets | $6,802,104 | $3,319,188 | | Total Assets | $8,455,666 | $5,082,549 | | Total Liabilities | $1,648,085 | $1,909,191 | | Total Stockholders' Equity | $6,807,581 | $3,173,358 | Condensed Consolidated Statements of Operations For the three months ended March 31, 2025, revenue decreased to $1.45 million from $1.79 million in the prior-year period, and a sharp increase in SG&A expenses led to a significant widening of the net loss to $1.24 million Statement of Operations (YoY Comparison) | Metric | Three months ended Mar 31, 2025 | Three months ended Mar 31, 2024 | | :--- | :--- | :--- | | Revenue | $1,449,377 | $1,790,521 | | Gross Profit | $615,940 | $717,583 | | Selling, general and administrative expenses | $1,854,316 | $805,042 | | Operating Loss | ($1,238,376) | ($87,459) | | Net Loss | ($1,240,590) | ($81,133) | | Net Loss per Share | ($0.32) | ($0.03) | Condensed Consolidated Statements of Cash Flows In Q1 2025, net cash used in operating activities was $1.56 million, offset by $4.7 million from financing activities, primarily IPO proceeds, resulting in a net cash increase of $3.1 million Cash Flow Summary (YoY Comparison) | Cash Flow From | For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | | :--- | :--- | :--- | | Operating Activities | ($1,561,698) | $6,839 | | Investing Activities | ($15,000) | ($44,656) | | Financing Activities | $4,698,682 | ($3,460,286) | | Net Increase (Decrease) in Cash | $3,121,984 | ($3,498,103) | | Cash at End of Period | $5,219,929 | $1,657,517 | - The primary source of cash in Q1 2025 was $4.68 million in net proceeds from the company's IPO and overallotment[13] Company Information and Disclosures About Callan JMB Inc. Callan JMB Inc. is an integrative logistics company focused on the healthcare and emergency management sectors, providing specialized services for medical materials - The company specializes in integrative logistics for the healthcare industry and emergency management agencies[5] - Core services include fulfillment, storage, monitoring, and cold chain logistics for medical materials[5] Forward-Looking Statement This press release includes forward-looking statements subject to risks and uncertainties, with actual results potentially differing materially from projections - The report contains forward-looking statements that are subject to risks and uncertainties, and actual results may differ[6] - Readers are advised to consult the company's Form S-1 Registration Statement for a full list of risk factors[6]